Acurx Pharmaceuticals (ACXP) Retained Earnings (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Retained Earnings for 7 consecutive years, with $87.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 16.06% year-over-year to $87.4 million; the trailing twelve-month figure through Jun 2026 stood at $87.4 million (up 16.06% YoY), and the FY2025 full-year result was $80.6 million, up 18.57% from the prior year.
• Retained Earnings climbed to $87.4 million in Q2 2026 per ACXP's latest filing, from $84.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $87.4 million in Q2 2026 and bottomed at $39.9 million in Q1 2022.
• Historically, Retained Earnings has averaged $62.2 million across 5 years, with a median of $64.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 35.73% in 2024, then rose 12.87% in 2025.
• Over 5 years, Retained Earnings stood at $45.9 million in 2022, then gained by 25.96% to $57.9 million in 2023, then grew by 17.39% to $67.9 million in 2024, then climbed by 18.57% to $80.6 million in 2025, then grew by 8.46% to $87.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $87.4 million, $84.0 million, and $80.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.